Isabella Martusciello

Isabella Martusciello

Auto-generated profile, based on publicly available information

Isabella Martusciello

Department of Life Sciences, University of Modena and Reggio Emilia, Via Giuseppe Campi 103-287, 41125 Modena, Italy

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 September 2025 in ACS Pharmacology & Translational Science
Verified
Journal Article
Open access
LBLaura Bertarini
Laura Bertarini
FIFederico Imbeni
Federico Imbeni
VBVirginia Brighenti
Virginia Brighenti
IMIsabella Martusciello
Isabella Martusciello
Federica PellatiFederica Pellati
Federica Pellati
Silvia AlboniSilvia Alboni
Silvia Alboni
p-Cresol (pC) is a phenolic compound to which humans can be exposed through both environmental sources, such as a pollutant, and endogenous production by the gut microbiota. Among microbial contributors, Clostridioides difficile appears to be a major source of pC within the body. Once absorbed, pC is highly protein-bound in plasma and predominantly circulates in its hepatic conjugated forms: p-cresyl sulfate (pCS) and p-cresol glucuronide (pCG), which are mainly excreted in urine. Accumulation of these metabolites, particularly pCS, classified as a protein-bound uremic toxin, has been associated with the progression of chronic kidney disease (CKD) and related complications, due to its pro-oxidant, pro-inflammatory, and pro-apoptotic properties. CKD patients are at increased risk for cognitive impairment, affective disorders, and central nervous system (CNS) dysfunctions. In recent years, increasing evidence has suggested a potential role of pC and its metabolites in CNS diseases. Here, we summarize current knowledge on the involvement of these compounds in the pathogenesis and progression of autism spectrum disorder, Parkinson's disease, Alzheimer's disease, and post-traumatic stress disorder. We also discuss how modulating systemic levels of pC may represent a promising strategy to improve pathological phenotypes in the context of neurodevelopmental and neurodegenerative disorders.

14 October 2026 in European Journal of Pharmacology
Verified
Journal Article
Open access
Giovanna RigilloGiovanna Rigillo
Giovanna Rigillo
CBCristina Benatti
Cristina Benatti
VRVERONICA RIVI
VERONICA RIVI
MCMiriam Ciani
Miriam Ciani
IMIsabella Martusciello
Isabella Martusciello
FTFabio Tascedda
Fabio Tascedda